Introduction {#s1}
============

The upper tract urothelial carcinoma (UTUC), which accounts for \~5% of all urothelial carcinoma, develops from the urothelium that lines the renal pelvis and the ureter ([@B1]). Although UTUCs share many similarities with bladder cancer, little is known about their pathogenesis, given the rarity of the disease. Radical nephroureterectomy (RNU) with bladder cuff excision is the gold standard curative therapy for localized UTUC; however, about 33% of patients with RNU will experience early tumor recurrence within 5 years ([@B2]), and the 5-years cancer-specific survival (CSS) is \<50% for patients with early-stage UTUC ([@B3]). The current predictive nomograms based on preoperative parameters may guide surgeons for decision-making regarding RNU with or without lymphadenectomy ([@B4]). However, predicting oncologic outcomes is another major concern in patients with UTUC. Because there are aggressive features characteristic to UTUC, a comprehensive recognition of the potential prognostic factors for survival is critical.

Lymphovascular invasion (LVI), which is defined as the presence of tumor cells within lymphatic or vascular channels, is a significant step in tumor distant metastasis ([@B5], [@B6]). According to the recommended European urology guidelines, LVI is an independent prognostic factor for bladder cancer using cystectomy specimens ([@B7]). In 2013, Ku et al. ([@B8]) performed a meta-analysis of 17 studies and confirmed the significant prognostic role of LVI in RNU specimens. However, much of the raw data in the included literature were lost in their paper. No additional study was conducted to determine the relationship between LVI and other clinicopathological features. In recent years, many studies have contributed relevant information toward the clinicopathological implications of LVI. The purpose of this study was to investigate the relationship between LVI and the clinical outcomes in patients with UTUC to enhance our understanding of prognostic values of LVI and facilitate efficient and prompt clinical decision-making for the patient.

Materials and Methods {#s2}
=====================

Literature Search Strategy
--------------------------

Using Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines ([@B9]), we (Z.L.Z. and H.Z.) conducted a computerized search using PubMed, EMBASE, and Web of Science in July 2019 to identify studies that documented the incidence of LVI in patients with UTUC undergoing RNU. The combination of the following keywords were used: ("upper urinary tract tumor" OR "renal pelvis" OR "ureter") AND ("radical nephroureterectomy") AND ("lymphovascular invasion") AND ("prognosis" OR "clinical outcome" OR "survival"). The language was restricted to English. At the same time, we manually screened the reference lists of the selected papers, including all of the relevant studies and reviews. For the data obtained from the published studies, no ethical approval and informed consent were required.

Study Inclusion and Exclusion Criteria
--------------------------------------

The following inclusion criteria were used to select eligible studies: (a) the diagnoses of UTUC and LVI were pathologically confirmed; (b) treatment was limited to RNU; (c) the prognostic values \[hazard ratios (HRs) and 95% confidence intervals (95% CIs)\] of LVI for overall survival (OS), CSS, recurrence-free survival (RFS), cancer-specific mortality (CSM), and recurrence risk were reported. Accordingly, the exclusion criteria of the meta-analysis were as follows: (a) studies that were not written in English; (b) meeting abstracts, reviews, review papers, or case reports; and (c) no sufficient data to estimate the HRs and 95% CIs. If more than one article from one patient cohort was identified, the most complete article was selected.

Data Extraction
---------------

Two authors (J.Y. and Y.J.F.) independently extracted data from the included studies using a predefined data extraction form. Discrepancies were resolved through discussion by a third author (B.W.). The following variables were recorded: patients\' characteristics (first author\'s name, year of publication, geographical region, number of patients, ages, gender, study period, and follow-up duration), tumor characteristics (TNM stage, tumor grade, LVI, lymph node metastasis, tumor multifocality, tumor necrosis, and positive surgical margin), and outcomes of interest. Our primary outcomes included OS, CSS, RFS, CSM, and recurrence. When multivariate analysis and univariate analysis results were both presented in one study, we chose the multivariate analysis results because they account for confounding factors and are more accurate.

Quality Assessment
------------------

The Newcastle Ottawa Scale (NOS) ([@B10]), which was recommended for evaluating non-randomized studies, was used to assess the quality of the selected studies. This scale assesses risk in three domains: patient selection, comparability of control and intervention groups, and assessment of outcomes. A score of 0--9 stars was allocated to each study. We defined high quality as a score of 6--9 and low quality as a score of \<6.

Statistical Analysis
--------------------

Effect measures for the outcomes of OS, CSS, RFS, CSM, and recurrence were HRs and 95% CIs extracted from the published studies. We studied the associations between LVI and clinicopathological parameters of UTUC. The numbers of events were obtained from the original studies, and the odds ratios (ORs) and the corresponding 95% CIs were calculated. The heterogeneity across studies was tested by using Cochran\'s Q test and Higgins ***I***-squared statistic. There was marked heterogeneity if *P* ≤ 0.10 and/or *I*^2^ was \>50%. A random-effects (RE) model was applied to pool results under significant heterogeneity; otherwise, a fixed-effects (FE) model was applied. A pooled HR ≥ 1 indicated poor survival for patients with an LVI expression. The source for interstudy heterogeneity was explored using subgroup analysis. Publication bias was evaluated by assessing the asymmetry of the funnel plot. Furthermore, Egger\'s test for funnel plots, which provides quantitative evidence, was employed to search for publication bias between the studies. To examine the stability and the reliability of the overall meta-analysis results, we performed the sensitivity analysis by excluding one study in turn. The statistical analyses were performed using Stata 12.0 software (Stat Corp, College Station, TX, USA). All *P*-values were two-sided, and *P* \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

Search Results
--------------

The initial search yielded 998 references, and 539 studies were excluded because of duplication. After title and/or abstracts were screened, 169 articles remained for full-text assessment, and 290 articles were excluded, including reviews, letters, meeting abstracts, and other articles irrelevant to our study. In accordance with the study inclusion criteria, 138 articles were excluded for repeated crowds or without enough extractable data. Finally, 31 studies, which were retrospective in design, were included in this meta-analysis. A flow diagram about the literature search and study selection process is presented in [Figure 1](#F1){ref-type="fig"}.

![PRISMA flow chart of literature search and selection process.](fonc-10-00487-g0001){#F1}

Features of Included Studies
----------------------------

The summary characteristics of these studies are shown in [Table 1](#T1){ref-type="table"}. A total of 14,653 patients with UTUC (range, 81--1,363) were included in the study. The median or mean age of patients ranged from 62 years to 71 years. The 31 included articles were published from 2009 to 2019. Geographically, 20 studies were conducted in Asia, 7 in multicenters worldwide, 2 in the USA, 1 in France, and 1 in Serbia. All of the patients had received RNU as their primary treatment for UTUC. Of these studies, 12 studies reported OS, 25 studies reported CSS, 15 studies reported RFS, 5 studies reported CSM, and 6 studies reported recurrence. The characteristics of tumor features and pathologic outcomes are summarized in [Table 2](#T2){ref-type="table"}. LVI was detected in 24.8% (3,635/14,653) of pathological specimens of the included patients. According to the NOS, we assessed the quality of the 31 eligible studies ([@B11]--[@B41]). The quality scores of the studies varied from 7 to 9, with a mean of 8.7; therefore, all of the studies were of high quality ([Supplementary Table 1](#SM4){ref-type="supplementary-material"}).

###### 

Clinical characteristics of the included studies in this meta-analysis.

  **References**              **Country**     **Recruitment period**   **No. of patients**   **Age (years)**                  **Gender (m/f)**   **Pelvicalyceal/ureteral/both**   **Follow-up (months)**             **Survival analysis**
  --------------------------- --------------- ------------------------ --------------------- -------------------------------- ------------------ --------------------------------- ---------------------------------- -----------------------
  Liu et al. ([@B11])         China           2005--2013               180                   Median (range) 67.2 (39--87)     109/71             NA                                Median (range) 45.4 (3--180)       RFS, CSS
  Li et al. ([@B12])          China           1999--2015               885                   Mean ± SD 66.9 ± 10.6            396/489            474/411                           Median (IQR) 61 (38--102)          CSS, OS
  Jan et al. ([@B13])         China           2007--2017               424                   Median (range) 70 (29--96)       189/235            191/138/95                        Median (IQR) 35 (14--60)           CSS, OS
  Aydin et al. ([@B14])       Muti--centers   1990--2008               348                   Median (IQR) 70 (64--77)         163/185            267/81                            Median 36                          RFS, CSS, OS
  Tan et al. ([@B15])         China           2003--2015               620                   Mean ± SD 65.7 ± 11.3            355/265            350/161/109                       Median (range) 51 (1--168)         RFS, CSS, OS
  Kohada et al. ([@B16])      Japan           1999--2016               148                   Median (IQR) 71 (64--78)         112/36             82/66                             Median (IQR) 35.5 (12--66)         RFS, CSS
  Abe et al. ([@B17])         Japan           2000--2015               214                   Median (range) 70.5 (35--93)     151/63             127/82/5                          Median (IQR) 41 (21--71)           RFS, CSS, OS
  Nakagawa et al. ([@B18])    Japan           1996--2013               109                   Median (IQR) 71 (64--77)         67/42              50/23/36                          Median (IQR) 46.5 (23.2--76.7)     RFS, CSS
  Inokuchi et al. ([@B19])    Japan           2005--2011               823                   Median (IQR) 71 (63--77)         578/245            434/375/14                        Median (IQR) 59.8 (23.3--66.2)     CSS, OS
  Ikeda et al. ([@B20])       Japan           1985--2013               399                   Median (IQR) 67 (62--75)         307/92             213/186                           Median (IQR) 43 (17--89)           RFS, CSS
  Fan et al. ([@B21])         China           2002--2013               101                   Median 69                        61/40              55/43/3                           Median (range) 41.3 (4.2--106.5)   RFS, CSS
  Cho et al. ([@B22])         Korea           2004--2015               1,049                 Median (IQR) 68.5 (60.5--74.3)   759/290            489/462/252                       Median (IQR) 40 (18.4--64.8)       RFS, CSS, OS
  Abufaraj et al. ([@B23])    Muti--centers   1990--2008               678                   Median (IQR) 69 (63--76)         380/298            478/200                           Median (IQR) 37.5 (20--66)         Recurrence, CSM
  Yan et al. ([@B24])         China           2002--2012               795                   NA                               462/333            497/187/111                       Median (IQR) 32 (17--60)           RFS, CSS, OS
  Kobayashi et al. ([@B25])   Japan           1990--2011               839                   Median (IQR) 70.4 (63--78)       610/229            NA                                Median (IQR) 34 (17--63)           Recurrence, CSS
  Kang et al. ([@B26])        Korea           2004--2014               566                   Median (IQR) 70 (62--75)         401/165            258/308                           Median) 33.8                       RFS, CSS, OS
  Fukushima et al. ([@B27])   Japan           2001--2015               81                    Median (range) 71 (41--87)       53/28              36/31/14                          Median (range) 41 (4--170)         CSS, OS
  Mathieu et al. ([@B28])     Muti--centers   1990--2008               732                   Median (IQR) 70 (63--76)         414/318            518/214                           Median (range) 35 (16--64)         RFS,CSS
  Lee et al. ([@B29])         Korea           1986--2013               344                   Mean ± SD 65.1 ± 10.6            240/104            146/147/51                        Median (range) 53.9 (1--297)       CSS, OS
  Lee et al. ([@B30])         China           2004--2010               250                   NA                               108/142            129/122                           Median 41                          CSS
  Park et al. ([@B31])        Korea           1991--2010               392                   Median (range) 64 (29--86)       299/93             NA                                Median (range) 47.6 (2--257)       RFS, CSS
  Lee et al. ([@B32])         Muti--centers   1991--2008               622                   Median (IQR) 69 (63--76)         346/276            452/170                           Median (IQR) 27 (12--53)           Recurrence, CSM
  Krabbe et al. ([@B33])      USA             2000--2012               122                   Median (range) 69 (35--92)       77/45              88/34                             Median (range) 32 (1--149)         CSS
  Kluth et al. ([@B34])       Muti--centers   1975--2012               242                   Median (IQR) 70 (63--77)         175/67             145/83/11                         Median 9                           CSM
  Liu et al. ([@B35])         China           1999--2010               421                   Median (IQR) 62 (51--70)         285/136            225/196                           NA                                 CSS
  Hurel et al. ([@B36])       France          1995--2010               551                   Median (IQR) 69.4 (61.8--76.4)   365/188            302/169/80                        Median (IQR) 26.8 (10.3--48.7)     RFS, CSS
  Milojevic et al. ([@B37])   Serbia          1999--2009               133                   Mean ± SD 66.7 ± 8.9             77/56              88/45                             Median (range) 35 (2--113)         Recurrence, CSS
  Godfrey et al. ([@B38])     USA             1990--2010               222                   Mean ± SD 70 ± 11.4              124/87             170/41                            Median (IQR) 27 (11--65.5)         OS
  Novara et al. ([@B39])      Muti--centers   1987--2008               762                   Median (IQR) 68 (61--75)         527/235            401/232/48                        Median (IQR) 34 (15--65)           Recurrence, CSM
  Kim et al. ([@B40])         Korea           1986--2006               238                   Median (range) 64.1 (25--91)     164/74             134/104                           Median (range) 64.1 (25--91)       RFS, CSS
  Margulis et al. ([@B41])    Muti--centers   1992--2006               1,363                 Mean ± SD 69.7 ± 11.1            921/442            878/463/22                        Median (range) 37.2 (1.2--250)     Recurrence, CSM

*m/f:male/femal; SD: standard deviation; NA, data not applicable; CSS: cancer-specific survival; OS: overall survival; RFS:recurrence-free survival; CSM: cancer-specific mortality*.

###### 

Tumor characteristics of the included studies in this meta-analysis.

  **Study**                   **Staging system**   **Grading system**   **LVI +/ LVI -**   **Stage 1-2/ 3-4**   **Grade 1-2/ 3**   **LNM-/ LNM+**   **Unifocal/ Multifocal**   **Papillary/ Sessile**   **TN+/ TN-**   **PSM+/ PSM-**
  --------------------------- -------------------- -------------------- ------------------ -------------------- ------------------ ---------------- -------------------------- ------------------------ -------------- ----------------
  Liu et al. ([@B11])         2008 AJCC            2016 WHO/ ISUP       28/152             115/65               91/89              169/11           173/7                      NA                       7/173          NA
  Li et al. ([@B12])          2002 AJCC            1973 WHO/ ISUP       46/839             623/262              518/367            823/62           NA                         771/114                  114/771        NA
  Jan et al. ([@B13])         2009 AJCC            2004 WHO/ ISUP       115/299            244/180              22/402             399/25           308/116                    97/278                   86/338         NA
  Aydin et al. ([@B14])       2002 AJCC            1998 WHO/ ISUP       98/250             191/157              NA                 314/34           270/78                     286/62                   62/286         NA
  Tan et al. ([@B15])         2002 AJCC            WHO/ ISUP            100/520            310/310              158/462            554/62           517/103                    193/427                  NA             50/570
  Kohada et al. ([@B16])      2002 AJCC            1998 WHO/ ISUP       55/93              82/66                60/88              140/8            148/0                      NA                       NA             12/136
  Abe et al. ([@B17])         2002 AJCC            1973 WHO/ ISUP       96/118             121/83               101/113            195/19           209/5                      NA                       NA             11/203
  Nakagawa et al. ([@B18])    2009 AJCC            2004 WHO/ ISUP       78/31              0/109                40/69              21/88            73/36                      NA                       NA             9/100
  Inokuchi et al. ([@B19])    2002 AJCC            NA                   252/52             459/324              444/379            787/26           809/14                     NA                       NA             34/789
  Ikeda et al. ([@B20])       2002 AJCC            1973 WHO/ ISUP       138/236            237/162              285/109            359/40           399/0                      NA                       NA             32/358
  Fan et al. ([@B21])         2002 AJCC            1998 WHO/ ISUP       14/87              47/54                25/76              92/9             91/10                      60/31                    NA             NA
  Cho et al. ([@B22])         2009 AJCC            1998 WHO/ ISUP       202/847            623/426              304/705            965/84           889/160                    NA                       NA             NA
  Abufaraj et al. ([@B23])    2002 AJCC            1973 WHO/ ISUP       135/543            452/226              174/504            629/49           533/145                    558/120                  597/81         NA
  Yan et al. ([@B24])         2010 AJCC            1998 WHO/ ISUP       169/626            390/405              212/583            711/84           684/111                    256/539                  NA             76/719
  Kobayashi et al. ([@B25])   AJCC                 1973 WHO/ ISUP       326/513            415/424              347/492            783/56           715/124                    NA                       NA             NA
  Kang et al. ([@B26])        AJCC                 1998 WHO/ ISUP       119/447            346/220              178/388            NA               517/49                     NA                       NA             NA
  Fukushima et al. ([@B27])   2002 AJCC            1973 WHO/ ISUP       50/31              37/44                31/50              74/7             67/14                      NA                       NA             NA
  Mathieu et al. ([@B28])     2002 AJCC            1998 WHO/ ISUP       153/579            480/252              187/454            677/55           577/155                    601/131                  97/635         NA
  Lee et al. ([@B29])         2010 AJCC            1998 WHO/ ISUP       86/258             144/200              53/291             265/79           293/51                     NA                       NA             NA
  Lee et al. ([@B30])         AJCC                 2004 WHO/ ISUP       60/190             166/84               57/193             232/18           191/59                     NA                       NA             NA
  Park et al. ([@B31])        1997 AJCC            1973 WHO/ ISUP       89/303             248/144              196/196            357/35           NA                         265/127                  NA             25/367
  Lee et al. ([@B32])         2002 AJCC            2004 WHO/ ISUP       140/482            396/226              164/458            569/53           498/124                    518/104                  85/537         NA
  Krabbe et al. ([@B33])      2010 AJCC            NA                   28/94              87/35                27/95              113/9            63/59                      80/42                    NA             NA
  Kluth et al. ([@B34])       2010 AJCC            2004 WHO/ ISUP       131/111            76/166               NA                 191/51           139/60                     83/47                    70/159         NA
  Liu et al. ([@B35])         2002 AJCC            1998 WHO/ ISUP       101/320            248/173              215/206            325/96           288/133                    NA                       NA             36/385
  Hurel et al. ([@B36])       2009 AJCC            1973 WHO/ ISUP       163/388            266/246              331/415            504/47           471/80                     NA                       NA             53/498
  Milojevic et al. ([@B37])   1997 AJCC            1998 WHO/ ISUP       78/55              47/86                46/87              128/5            86/47                      NA                       NA             NA
  Godfrey et al. ([@B38])     2010 AJCC            1998 WHO/ ISUP       68/143             137/74               77/134             197/14           NA                         NA                       NA             18/193
  Novara et al. ([@B39])      2002 AJCC            1973 WHO/ ISUP       148/614            508/254              320/442            713/49           633/48                     NA                       NA             NA
  Kim et al. ([@B40])         1997AJCC             1973 WHO/ ISUP       31/207             131/107              95/143             NA               182/56                     185/53                   NA             10/228
  Margulis et al. ([@B41])    2002 AJCC            1998 WHO/ ISUP       338/1,025          852/511              495/868            455/135          1,341/22                   983/380                  294/1,069      NA

*NA, data not applicable; AJCC, American Joint Committee on Cancer classification; WHO/ ISUP:World Health Organization/International Society of Urological Pathology classification; LVI, Lymphovascular Invasion; LNM, Lymph node metastasis; TN, Tumor necrosis; PSM, Positive surgical margin*.

Meta-Analysis Results
---------------------

The pooled results indicated that the presence of LVI in UTUC specimens was associated with poor CSS (RE model, HR = 1.59, 95% CI: 1.45--1.74, *p* \< 0.001; *I*^2^ = 77%) ([Figure 2](#F2){ref-type="fig"}), OS (RE model, HR = 1.55, 95 % CI: 1.41--1.71, *p* \< 0.001; ***I***^**2**^= 73.2%) ([Figure 3A](#F3){ref-type="fig"}), RFS (RE model, HR = 1.46, 95 % CI: 1.32--1.61, *p* \< 0.001; *I*^2^ = 78.6%) ([Figure 3B](#F3){ref-type="fig"}), CSM (RE model, HR=1.25, 95 % CI: 1.00--1.56, *p* = 0.047; *I*^2^ = 91.6%) ([Figure 3C](#F3){ref-type="fig"}), and recurrence (RE model, HR=1.23, 95 % CI: 1.03--1.48, *p* = 0.026; *I*^2^ = 89%) ([Figure 3D](#F3){ref-type="fig"}). To explore the heterogeneity for CSS, OS, and RFS, the prognostic value of LVI was evaluated using subgroup analysis under the geographical region (Asia vs. non-Asian), year of publication (≥2014 vs. \<2014), TNM stage (T3+T4 %) (≥40 vs. \<40), tumor grade (G2+G3 %) (≥60 vs. \<60), number of patients (≥500 vs. \<500), and median follow-up (≥ 40 months vs. \<40 months) ([Table 3](#T3){ref-type="table"}). Because of the few cohorts in the CSM and recurrence groups, no subgroup analysis was conducted. The results in the subgroup analysis were consistent with the primary findings, which suggested that LVI was a prognostic factor despite heterogeneity among some groups. Although no significant changes for the interstudy heterogeneity were detected, the observed heterogeneity dropped significantly in some subgroup models, such as the number of patients \<500 and Grade (G3+G4 %) ≥60.

![Meta-analysis of the effect of LVI on CSS.](fonc-10-00487-g0002){#F2}

![Forest plots assessing the correlation of LVI and **(A)** OS, **(B)** RFS, **(C)** CSM, and **(D)** recurrence in studies considering patients with UTUC.](fonc-10-00487-g0003){#F3}

###### 

Summary and subgroup analysis of pooled ORs for the eligible studies.

  **Analysis specification**   **No. of studies**   **Study heterogeneity**   **Effects model**   **Pooled HR(95% CI)**   ***P*-Value**     
  ---------------------------- -------------------- ------------------------- ------------------- ----------------------- ----------------- ---------
  **CSS**                                                                                                                                   
  Overall                      24                   69.9                      \<0.001             Random                  1.62(1.49,1.76)   \<0.001
  Geographical region                                                                                                                       
  Asia                         19                   65.1                      \<0.001             Random                  1.66(1.52,1.81)   \<0.001
  non-Asian                    5                    82.5                      \<0.001             Random                  1.51(1.19,1.91)   0.001
  Year of publication                                                                                                                       
  ≥ 2014                       16                   74                        \<0.001             Random                  1.67(1.49,1.86)   \<0.001
  \<2014                       8                    59.4                      0.016               Random                  1.55(1.37,1.76)   \<0.001
  No. of patients                                                                                                                           
  ≥ 500                        9                    77.5                      \<0.001             Random                  1.83(1.63,2.06)   \<0.001
  \<500                        15                   34.8                      0.090               Fixed                   1.45(1.33,1.59)   \<0.001
  Stage (T~3~+T~4~ %)                                                                                                                       
  ≥ 40                         16                   68.8                      \<0.001             Random                  1.64(1.49,1.81)   \<0.001
  \<40                         8                    74.3                      \<0.001             Random                  1.58(1.34,1.87)   0.001
  Grade (G~2~+G~3~ %)                                                                                                                       
  ≥ 60                         15                   51.6                      0.011               Random                  1.60(1.48,1.73)   \<0.001
  \<60                         9                    82.9                      \<0.001             Random                  1.70(1.39,2.07)   \<0.001
  Median follow-up                                                                                                                          
  ≥ 40 months                  14                   72.1                      \<0.001             Random                  1.65(1.45,1.88)   \<0.001
  \<40 months                  10                   69                        \<0.001             Random                  1.59(1.42,1.78)   \<0.001
  **OS**                                                                                                                                    
  Overall                      12                   73.2                      \<0.001             Random                  1.55(1.41,1.71)   \<0.001
  Geographical region                                                                                                                       
  Asia                         10                   76.5                      \<0.001             Random                  1.56(1.40,1.74)   \<0.001
  non-Asian                    2                    61.0                      0.109               Random                  1.49(1.11,2.00)   \<0.001
  Year of publication                                                                                                                       
  ≥ 2014                       10                   77.6                      \<0.001             Random                  1.54(1.37,1.73)   \<0.001
  \<2014                       2                    0                         0.402               Fixed                   1.58(1.40,1.77)   \<0.001
  No. of patients                                                                                                                           
  ≥ 500                        4                    83.1                      \<0.001             Random                  1.71(1.48,1.97)   \<0.001
  \<500                        8                    33.9                      0.169               Fixed                   1.43(1.29,1.59)   \<0.001
  Stage (T~3~+T~4~ %)                                                                                                                       
  ≥ 40                         10                   71.2                      \<0.001             Random                  1.60(1.45,1.78)   \<0.001
  \<40                         2                    80.1                      0.025               Random                  1.33(0.99,1.80)   0.061
  Grade (G~3~+G~4~ %)                                                                                                                       
  ≥ 60                         9                    0                         0.449               Fixed                   1.58(1.50,1.66)   \<0.001
  \<60                         3                    93.8                      \<0.001             Random                  1.54(0.92,2.58)   0.098
  Median follow-up                                                                                                                          
  ≥ 40 months                  7                    82.6                      \<0.001             Random                  1.54(1.30,1.81)   \<0.001
  \<40 months                  5                    29.4                      0.225               Fixed                   1.60(1.47,1.75)   \<0.001
  **RFS**                                                                                                                                   
  Overall                      15                   78.6                      \<0.001             Random                  1.46(1.32,1.61)   \<0.001
  Geographical region                                                                                                                       
  Asia                         12                   69.3                      \<0.001             Random                  1.52(1.38,1.67)   \<0.001
  non-Asian                    3                    91.8                      \<0.001             Random                  1.28(0.94,1.74)   0.114
  Year of publication                                                                                                                       
  ≥ 2014                       11                   75.8                      \<0.001             Random                  1.50(1.34,1.67)   \<0.001
  \<2014                       4                    86.4                      \<0.001             Random                  1.38(1.09,1.74)   0.007
  No. of patients                                                                                                                           
  ≥ 500                        7                    88.2                      \<0.001             Random                  1.57(1.36,1.81)   \<0.001
  \<500                        8                    29.6                      0.192               Fixed                   1.34(1.20,1.49)   \<0.001
  Stage (T~3~+T~4~ %)                                                                                                                       
  ≥ 40                         11                   68.9                      0.061               Random                  1.57(1.31,1.88)   \<0.001
  \<40                         4                    82.7                      0.026               Random                  1.84(0.95,3.53)   0.068
  Grade (G~3~+G~4~ %)                                                                                                                       
  ≥ 60                         4                    45.8                      \<0.001             Random                  1.38(1.25,1.51)   \<0.001
  \<60                         2                    54.1                      0.001               Random                  1.71(1.36,2.15)   \<0.001
  Median follow-up                                                                                                                          
  ≥ 40 months                  9                    46.8                      0.059               Random                  1.42(1.30,1.57)   \<0.001
  \<40 months                  6                    89.2                      \<0.001             Random                  1.48(1.23,1.79)   \<0.001

The risk estimate with pooled ORs was used to assess the associations between the LVI and the clinicopathological parameters in patients with UTUC. As shown in [Table 4](#T4){ref-type="table"}, LVI was significantly related to TNM stage (III/IV vs. I/II: OR = 7.63, 95% CI: 5.60--10.39, *p* \< 0.001) ([Supplementary Figure 1A](#SM1){ref-type="supplementary-material"}), higher tumor grade (3 vs. 1/2: OR = 5.61, 95% CI: 3.71--8.48, *p* \< 0.001) ([Supplementary Figure 1B](#SM1){ref-type="supplementary-material"}), lymph node metastasis (LNM) (yes vs. no: OR = 4.95, 95% CI: 3.66--6.71, *p* \< 0.001) ([Supplementary Figure 1C](#SM1){ref-type="supplementary-material"}), concomitant carcinoma *in situ* (CIS) (yes vs. no: OR = 1.92, 95% CI: 1.36--2.70, *p* \< 0.001) ([Supplementary Figure 1D](#SM1){ref-type="supplementary-material"}), and positive surgical margin (PSM) (yes vs. no: OR = 4.38, 95% CI: 2.71--7.07, *p* \< 0.001) ([Supplementary Figure 1E](#SM1){ref-type="supplementary-material"}), but not related to gender (male vs. female: OR = 0.98, 95% CI: 0.80--1.19, *p* = 0.825) ([Supplementary Figure 2A](#SM2){ref-type="supplementary-material"}) and multifocality (multifocal vs. unifocal: OR = 1.09, 95% CI: 0.82--1.46, *p* = 0.555) ([Supplementary Figure 2B](#SM2){ref-type="supplementary-material"}). No significant heterogeneity was observed in those groups. In sensitivity analyses omitting enrolled studies in turn, the results showed that the pooled HRs did not alter significantly, which suggested that the findings were reliable and robust ([Supplementary Figure 3](#SM3){ref-type="supplementary-material"}).

###### 

Meta-analysis of LVI and clinicopathological features in patients with UTUC.

  **Variables**                             **Studies**   **Pooled OR (95% CI)**   ***P*~**Value**~**   **Model**   **Heterogeneity *I^**2**^* (%)**   ***P ~***Heterogeneity***~***
  ----------------------------------------- ------------- ------------------------ -------------------- ----------- ---------------------------------- -------------------------------
  TNM stage (III/IV vs. I/II)               7             7.63 (5.60--10.39)       \<0.001              RE          44.2                               0.097
  Tumor grade (3 vs. 1/2)                   7             5.61 (3.71--8.48)        \<0.001              RE          45.2                               0.090
  Lymph node metastasis (yes vs. no)        6             4.95 (3.66--6.71)        \<0.001              FE          0                                  0.625
  Carcinoma *in situ* (yes vs. no)          4             1.92 (1.36--2.70)        \<0.001              FE          0                                  0.826
  Positive surgical margin (yes vs. no)     3             4.38 (2.71--7.07)        \<0.001              FE          0                                  0.794
  Multifocality (multifocal vs. unifocal)   6             1.09 (0.82--1.46)        0.555                FE          36.1                               0.166
  gender (male vs. female)                  7             0.98 (0.80--1.19)        0.825                FE          0                                  0.675

Publication Bias
----------------

We conducted the publication bias assessment of the studies using funnel plots and Egger\'s test. As shown in [Figure 4](#F4){ref-type="fig"}, no obvious asymmetry was observed in all of the groups. The *P* values of the Egger\'s test were all \>0.05 in CSS (*p*-Egger = 0.977) ([Figure 4A](#F4){ref-type="fig"}), OS (*p*-Egger = 0.330) ([Figure 4B](#F4){ref-type="fig"}), RFS (*p*-Egger = 0.811) ([Figure 4C](#F4){ref-type="fig"}), CSM (*p*-Egger = 0.984) ([Figure 4D](#F4){ref-type="fig"}), and recurrence (*p*-Egger = 0.843) ([Figure 4E](#F4){ref-type="fig"}).

![Funnel plots evaluating possible publication bias regarding **(A)** CSS, **(B)** OS, **(C)** RFS, **(D)** CSM, and **(E)** recurrence.](fonc-10-00487-g0004){#F4}

Discussion {#s4}
==========

UTUC is a rare urothelial carcinoma compared with bladder cancer; however, the incidence of UTUC has increased significantly in the last decade ([@B42]). Although we have made great strides to understand UTUC, its management remains challenging. Even after the standard RNU surgery was performed in the majority of patients with UTUC, there were still some patients with poor postoperative outcomes. Therefore, it is very important to accurately predict the clinical prognosis of patients with UTUC after RNU. To date, many studies have been conducted to identify the significant prognostic factors of UTUC. Several traditional prognostic predictors, such as pathologic characteristics of RNU specimens including tumor stage and grade ([@B40]), tumor architecture ([@B21]), tumor size ([@B24]), and CIS ([@B43]), have been identified as significant prognostic variables for CSS and RFS in different studies.

LVI was considered to be the first step in the metastasis of tumor cells and LNM ([@B30]). Recently, mounting evidence has indicated that LVI is associated with poor prognosis for many types of tumors, such as liver, bladder, and prostate cancer ([@B7], [@B44]). Jiang et al. ([@B6]) reported that LVI is an independent prognostic factor for predicting worse progression in prostate cancer, and they recommended that LVI should be reported in the final pathological diagnosis after radical prostatectomy. Similarly, Canter et al. ([@B45]) found that the presence of LVI in the final pathological reports for bladder cancer delivers significant risks for worse CSS and OS. Several studies have suggested that LVI can be used as an independent prognostic factor in patients with UTUC after RNU ([@B29], [@B36]). However, some studies have suggested that the prognostic value of LVI in assessing survival outcome is meaningless ([@B28], [@B46]). The possible outcomes of these few negative papers may have been related to the heterogeneity of UTUC biology and different clinicopathological features.

Based on the findings of previous research, \~15%−30% of patients with UTUC after surgery have a positive rate of LVI in the final pathology report ([@B8], [@B30], [@B39]). Consistent with results in previous reports, we found that LVI appeared in \~24.8% of patients. LVI is an easily accessible pathological parameter, which can be accurately measured among observers. Hurel et al. ([@B36]), in their study involving 551 patients, concluded that the presence of LVI was an independent risk factor for UTUC. Likewise, Lee et al. ([@B30]) reported a significant association between LVI and tumor grade, tumor stage, and LNM. Although it has been proposed that LVI should be accurately recorded in the pathological reports for UTUC specimens, there are still controversial data regarding the impact of LVI on patient prognosis and survival. For example, Jan et al. ([@B13]) recently reported that LVI was not associated with OS and CSS in a multivariate analysis. Eich et al. ([@B47]) found that LVI was not associated with tumor progression, total mortality, and CSM.

Although the previous studies had largely enhanced our knowledge of UTUC, they were limited to small sample sizes and heterogeneous populations. To overcome these shortcomings and better understand the clinical value of LVI, we assessed LVI and 14,653 patients treated with RNU for UTUC using a meta-analysis. In this study, we demonstrated that LVI was an independent prognostic factor for CSS, RFS, OS, CSM, and recurrence among patients with UTUC treated with RNU. In several studies, LVI has been related to worse tumor differentiation, higher stage and grade, LNM, and PSMs. Consistent with findings in previous outcomes ([@B11], [@B30], [@B36]), our results indicated that LVI was associated with clinicopathological features, which are all independent poor prognostic factors. All of the results strongly supported the prognostic value of LVI with regard to poor outcomes in UTUC and its role in tumor progression. Furthermore, the results of the study may provide a postoperative follow-up protocol for patients with UTUC to evaluate the prognostic value of LVI. Interestingly, no obvious association between LVI, and multifocality was found in our study. Although multifocal tumors had a worse oncological outcome than renal pelvic tumors, the role of tumor location has not yet been confirmed ([@B39], [@B48]). Hence, multifocal tumors may develop from a more aggressive carcinogenesis pathway.

The results obtained in this study are mainly consistent with the outcomes in a previous system review by Ku et al. ([@B8]). However, our study presented a series of advancements. At first, the search time by Ku et al. ended in 2013. However, we added 23 extra studies including 10,963 patients, thereby allowing us to perform a subgroup analysis with more exact evaluation for LVI. Besides, the quality as assessed by NOS in the present meta-analysis was greater, which strengthened the persuasiveness of this research. With the stupendous prognostic value of LVI, we suggest that LVI should always be presented in the pathologic report of RNU specimens. Moreover, patients with LVI expression may be given intensive treatment after RNU. Currently, there is insufficient evidence to recommend adjuvant chemotherapy (AC) as a treatment strategy for patients with UTUC ([@B49]). Lee et al. ([@B29]) showed that AC does not reduce mortality in patients with UTUC. However, in the subgroup of patients with LVI, AC could significantly improve CSS and OS. Unfortunately, we are unable to further explore the relationship between LVI and AC due to the insufficient data in this study.

Our study has several limitations that should be acknowledged. First, the literature was mainly retrospective, with an obvious heterogeneity in our study. A subgroup analysis that aimed to identify the source of heterogeneity was conducted in the present study. Although considerable heterogeneity among studies had no effect on the pooled results, heterogeneity should not be completely neglected. Thus, the conclusions yielded in this study must be interpreted with caution. Second, the studies in our paper were mainly conducted in four regions. The observed differences in the statistical results might reflect regional ethnic differences. Third, other potential risk factors involved in this report may have affected the final results. For example, the surgical methods were different. Most RNUs were laparoscopic approaches, but some were performed by open surgeries. Thus, there may be performance bias. Fourth, reporting bias may exist in our research, as some studies with negative results may not have been published. However, no significant bias was observed in this research, which indicates that our results were stable and reliable.

Conclusion {#s5}
==========

In summary, LVI is associated with unfavorable prognosis and clinicopathological features in patients with UTUC. Given its convenience and inexpensiveness in clinical application, LVI could be a useful tool for predicting prognosis and outcomes of patients with UTUC. However, additional prospective, multicenter studies should be conducted to confirm our findings and address the limitations observed in our meta-analysis.

Data Availability Statement {#s6}
===========================

All data generated or analyzed during this study are included in this published article.

Author Contributions {#s7}
====================

LZ project development and manuscript writing. BW data management and manuscript editing. JY and YF data collection. ZZ and HZ data analysis and data management.

Conflict of Interest {#s8}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material {#s9}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2020.00487/full#supplementary-material>

###### 

Forest plots of meta-analyses of the association between LVI and clinicopathological features in UTUC: **(A)** TNM stage, **(B)** tumor grade, **(C)** LNM, **(D)** CIS, and **(E)** PSM.
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Forest plots of meta-analyses of the association between LVI and clinicopathological features in UTUC: **(A)** gender and **(B)** multifocality.
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Sensitivity analysis in this meta-analysis. **(A)** Sensitivity analysis for CSS; **(B)** sensitivity analysis for OS; **(C)** sensitivity analysis for RFS; **(D)** sensitivity analysis for CSM; and **(E)** sensitivity analysis for recurrence.
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LVI

:   lymphovascular invasion

UTUC

:   upper tract urinary carcinoma

RNU

:   radical nephroureterectomy

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

NOS

:   Newcastle-Ottawa scale

HRs

:   hazard ratios

ORs

:   odds ratio

CIs

:   confidence intervals

CSS

:   cancer-specific survival

OS

:   overall survival

RFS

:   recurrence-free survival

CSM

:   cancer-specific mortality

CIS

:   concomitant carcinoma *in situ*

LNM

:   lymph node metastasis

PSM

:   positive surgical margin

AC

:   adjuvant chemotherapy.
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